Positron emission tomography imaging in nonmalignant thoracic disorders

Area of Science:

• Nuclear Medicine
• Thoracic Imaging
• Oncology

Background:

• Fluorodeoxyglucose-positron emission tomography (FDG-PET) is established in lung cancer management.
• Emerging evidence highlights FDG-PET's utility in diagnosing various benign pulmonary disorders.
• Accurate differentiation between benign and malignant chest diseases is critical.

Purpose of the Study:

• To review the technical factors for optimal thoracic FDG-PET imaging.
• To emphasize the role of attenuation correction (AC) and co-registration with anatomic images.
• To comprehensively outline FDG-PET applications in diagnosing and managing benign and malignant thoracic conditions.

Main Methods:

• Review of technical aspects including attenuation correction and image co-registration.
• Analysis of physiological FDG uptake patterns in thoracic structures.
• Evaluation of FDG-PET in differentiating benign vs. malignant nodules using dual time point imaging and partial volume correction.
• Assessment of FDG-PET in environment-induced lung diseases, infections, and inflammatory conditions.
• Review of FDG-PET's role in pleural diseases and asbestosis-related disorders.

Main Results:

• Optimal thoracic imaging requires attention to technical factors like AC and co-registration.
• FDG-PET demonstrates characteristic uptake patterns in various benign and malignant thoracic conditions.
• Dual time point imaging and partial volume correction improve nodule assessment accuracy.
• FDG-PET is valuable for diagnosing and monitoring lung infections, inflammatory diseases, and pleural disorders.

Conclusions:

• FDG-PET is a powerful tool for diagnosing a wide spectrum of benign and malignant pulmonary and pleural diseases.
• Understanding technical nuances and physiological uptake is key to accurate interpretation.
• FDG-PET significantly enhances the ability to differentiate benign from malignant thoracic pathologies.